DOCSLIB.ORG

Chelation Therapy in the Treatment of Metal Intoxication Page Left Intentionally Blank Chelation Therapy in the Treatment of Metal Intoxication

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chelation Therapy in the Treatment of Metal Intoxication Page Left Intentionally Blank Chelation Therapy in the Treatment of Metal Intoxication Chelation Therapy in the Treatment of Metal Intoxication Page left intentionally blank Chelation Therapy in the Treatment of Metal Intoxication Jan Aaseth Department of Public Health Hedmark University College, Elverum Department of Internal Medicine Innlandet Hospital, Kongsvinger Hedmark, Norway Guido Crisponi Department of Chemical and Geological Sciences University of Cagliari Cagliari, Italy Ole Andersen Department of Science and Environment Roskilde University Roskilde, Denmark AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an Imprint of Elsevier Academic Press is an imprint of Elsevier 125 London Wall, London EC2Y 5AS, UK 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA 50 Hampshire Street, 5th Floor, Cambridge, MA 02139, USA The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK Copyright © 2016 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, elec- tronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions. This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein). Notices Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treat- ment may become necessary. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, includ- ing parties for whom they have a professional responsibility. To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress ISBN: 978-0-12-803072-1 For information on all Academic Press publications visit our website at https://www.elsevier.com/ Typeset by Thomson Digital Contents Contributors xi Preface xiii List of Abbreviations xv 1. General Chemistry of Metal Toxicity and Basis for Metal Complexation Jan Aaseth, Lars Gerhardsson, Marit Aralt Skaug, Jan Alexander 1.1 General Chemistry of Metals 1 1.2 Essential and Nonessential Elements 3 1.3 Effects of Toxic Exposure of an Essential or Nonessential Metal 7 1.3.1 Basic Concepts in Chemical Toxicity Testing 7 1.3.2 Exposure Patterns and Mechanisms of Metal Toxicity 10 1.3.3 Gastrointestinal Effects of Metal Exposure 11 1.3.4 Respiratory Effects of Metal Exposure 11 1.3.5 Hepatic and Renal Effects 12 1.3.6 Effects on the Nervous System 13 1.3.7 Hematological Effects 14 1.3.8 Cardiovascular Effects 15 1.3.9 Metal Allergies 15 1.3.10 Carcinogenic Effects 15 1.4 Basis for Metal Complex Formation with Endogenous and Exogenous Ligands 16 1.5 Endogenous Complexing and Detoxification Compounds 20 1.5.1 Albumin 20 1.5.2 Transferrin and Ferritin 21 1.5.3 Glutathione 24 1.5.4 Metallothionein 26 1.5.5 Selenoproteins 28 1.6 Conclusions 28 References 29 2. Chelating Agents as Therapeutic Compounds—Basic Principles Guido Crisponi, Valeria Marina Nurchi 2.1 Chemical and Biological Principles for in Vivo Chelation 35 2.1.1 Stability 36 2.1.2 Selectivity 38 v vi Contents 2.1.3 Kinetic Aspects of Chelation 39 2.1.4 Absorption and Bioavailability of Chelating Agents 41 2.2 Chelating Agents: Chemistry, Kinetics, and Toxicology 41 2.2.1 BAL, DMPS, DMSA 42 2.2.2 D-penicillamine 46 2.2.3 Triethylenetetramine 49 2.2.4 Deferoxamine, Deferiprone, and Deferasirox 50 2.2.5 EDTA and DTPA 53 2.2.6 Prussian Blue 56 References 57 3. Diagnosis and Evaluation of Metal Poisonings and Chelation Therapy Petr Dusek, Jan Aaseth 3.1 Introduction 63 3.2 History of Symptoms and Exposure 63 3.3 Clinical Findings 66 3.4 Genetic Disorders with Systemic Metal Accumulation 71 3.5 Toxicological Analyses 73 3.6 Biochemical Measurements 75 3.7 Physiological, Radiological, and Ultrasonographic Investigations 76 References 78 4. Chelation Treatment During Acute and Chronic Metal Overexposures—Experimental and Clinical Studies Ole Andersen 4.1 Introduction 86 4.2 Aluminum 88 4.2.1 Selected Representative Animal Studies 93 4.2.2 Selected Representative Clinical Studies 95 4.2.3 Conclusions 97 4.3 Antimony 97 4.3.1 Animal Experiments 98 4.3.2 Clinical Cases 99 4.3.3 Conclusion 101 4.4 Arsenic 101 4.4.1 Selected Animal Experiments 102 4.4.2 Clinical Studies 107 4.4.3 Discussion and Conclusion 112 4.5 Beryllium 113 4.5.1 Experimental Chelation Studies 114 4.5.2 Clinical Experience 116 4.5.3 Conclusion 116 Contents vii 4.6 Bismuth 116 4.6.1 Animal Chelation Studies 117 4.6.2 Clinical Chelation Studies 118 4.6.3 Conclusion 120 4.7 Cadmium 120 4.7.1 Animal Chelation Experiments 121 4.7.2 Clinical Chelation Studies 124 4.7.3 Conclusion 124 4.8 Chromium 124 4.8.1 Animal Experimental Studies 125 4.8.2 Clinical Cases 127 4.8.3 Conclusion 129 4.9 Cobalt 129 4.9.1 Chelation, Animal Experiments 130 4.9.2 Chelation, Clinical Studies 132 4.9.3 Conclusions 132 4.10 Copper 133 4.10.1 Animal Chelation Studies 135 4.10.2 Human Clinical Chelation Studies 135 4.10.3 Conclusions 137 4.11 Gallium 137 4.11.1 Experimental Animal Chelation Studies 138 4.11.2 Clinical Chelation 139 4.11.3 Conclusions 139 4.12 Gold 139 4.12.1 Animal Experimental Studies 140 4.12.2 Clinical Studies 142 4.12.3 Conclusions 143 4.13 Iron 144 4.13.1 Selected Animal Studies 145 4.13.2 Clinical Chelation Cases 146 4.13.3 Clinical Reviews 149 4.13.4 Conclusions 150 4.14 Lead 151 4.14.1 Animal Chelation Studies 153 4.14.2 Clinical Studies 157 4.14.3 Summary and Conclusions 165 4.15 Manganese 166 4.15.1 Animal Experimental Chelation Studies 167 4.15.2 Clinical Chelation Studies 168 4.15.3 Conclusion 168 4.16 Mercury 169 4.16.1 Experimental Animal Studies 171 4.16.2 Clinical Studies 174 4.16.3 Conclusions 184 4.17 Nickel 185 4.17.1 Experimental Chelation Studies 186 viii Contents 4.17.2 Clinical Studies 189 4.17.3 Conclusions 191 4.18 Platinum 192 4.18.1 Experimental Animal Studies 194 4.18.2 Clinical Studies 195 4.18.3 Conclusions 195 4.19 Silver 196 4.20 Thallium 197 4.20.1 Animal Studies 200 4.20.2 Clinical Cases 201 4.20.3 Conclusions 203 4.21 Tin 203 4.21.1 Animal Experimental and Clinical Studies 205 4.21.2 Conclusions 205 4.22 Zinc 205 4.22.1 Experimental and Clinical Chelation Studies 207 4.22.2 Conclusions 208 4.23 Summary, Conclusions, and Perspectives 208 References 210 5. Decorporation of Radionuclides Ole Andersen 5.1 Introduction 253 5.2 Americium 255 5.3 Cesium 258 5.4 60Cobalt 260 5.5 Plutonium 261 5.6 Polonium 265 5.7 Radium 269 5.8 Strontium 270 5.9 Technetium 271 5.10 Thorium 271 5.11 Uranium 273 5.12 Development of New Chelators and Off-Label Use of Chelating Agents 277 5.13 Conclusions and Perspectives 278 References 279 6. Chelating Therapy in Metal Storage Diseases Petr Dusek, Jan Aaseth 6.1 Introduction 286 6.2 Wilson’s Disease 286 6.2.1 Penicillamine in Wilson’s Disease 287 6.2.2 Trientine Treatment—The Treatment of Choice Today? 287 Contents ix 6.2.3 Ammonium Tetrathiomolybdate—An Alternative Agent? 288 6.2.4 Zinc—An Agent for Maintenance Therapy 289 6.2.5 Dimercaptosuccinic Acid (DMSA)—Useful in Wilson’s Disease? 289 6.2.6 Liver Transplantation 290 6.2.7 Conlusive Guidelines for Therapeutic Monitoring of Wilson’s Disease 290 6.3 Other Neurodegenerative Diseases 291 6.3.1 Friedreich’s Ataxia 291 6.3.2 Aceruloplasminemia 292 6.3.3 Pantothenate Kinase Associated Neurodegeneration 295 6.3.4 Other Neurodegenerations with Brain Iron Accumulation 296 6.3.5 Parkinson’s Disease 298 6.3.6 Demyelinating Disorders and Neuroinflammation 299 6.4 Transfusional and Hereditary Siderosis—Including Thalassemias 300 6.4.1 Deferoxamine (Desferrioxamine) in Transfusional Siderosis 301 6.4.2 Deferiprone Therapy 302 6.4.3 Deferasirox 302 6.4.4 Bone Marrow Transplantation in Thalassemia 303 6.4.5 Hemochromatosis—and Therapeutic Elimination by the Endogenous “Heme Chelate” 304 6.5 Concluding Remarks 304 References 305 7. Guidance for Clinical Treatment of Metal Poisonings—Use and Misuse of Chelating Agents Lars Gerhardsson, Jan Aaseth 7.1 Introduction 314 7.2 Reducing the Absorbed Dose 314 7.2.1 Removal From Exposure 314 7.2.2 Removal of Toxic Element From the Gastrointestinal Tract 315 7.2.3 Use of Gastric Lavage, Activated Charcoal, or Unabsorbed Resins 315 7.3 General Supportive Therapy 316 7.3.1 Maintenance of Respiration and Circulation 316 7.3.2 Maintenance of Water and Electrolyte Balance 316 7.3.3 Control of Cerebral Functions 317 7.4 Elimination of Absorbed Poison 317 7.4.1 Diuresis 317 7.4.2 Biliary Excretion 317 7.4.3 Dialysis 318 7.4.4 Exchange
Load more

Recommended publications
  • Effects of Calcium Chelation on Digitalis-Induced Cardiac Arrhythmias by Paul Szekely and N
    Br Heart J: first published as 10.1136/hrt.25.5.589 on 1 September 1963. Downloaded from Brit. Heart J., 1963, 25, 589. EFFECTS OF CALCIUM CHELATION ON DIGITALIS-INDUCED CARDIAC ARRHYTHMIAS BY PAUL SZEKELY AND N. A. WYNNE From the Cardiovascular Department, Newcastle General Hospital, and the Department ofPhysiology, King's College, University of Durham Received November 19, 1962 Several studies have already shown that cardiac arrhythmias caused by digitalis can be abolished by the induction of hypocalcaemia (Page and Real, 1955; Smith and Grinnell, 1955; Gubner and Kallman, 1957; Kabakow and Brothers, 1958; Surawicz et al., 1959; Cohen et al., 1959; Rosenbaum, Mason, and Seven, 1960; Surawicz, 1960; Soffer, Toribara, and Sayman, 1961). The rationale of inducing hypocalcemia as an anti-arrhythmic measure is based on experimental and clinical obser- vations relating to the direct myocardial action of calcium and to the interaction between calcium, potassium, and digitalis. Low calcium concentration decreases myocardial irritability (Brooks et al., 1955) and it also increases the intracellular potassium concentration (Rosenbaum et al., 1960). There is also a synergistic action between calcium and digitalis, which was observed in the presence of digitalis intoxication (Nalbandian et al., 1957). The present study was undertaken copyright. in order to assess the value of induced hypocalcemia in the management of cardiac arrhythmias caused by digitalis. MATERIAL AND METHODS Forty-eight experiments were carried out under general aneesthesia on 46 cats and 2 dogs. Cardiac arrhythmia was induced by the intravenous administration of tincture of digitalis as previously described http://heart.bmj.com/ (Szekely and Wynne, 1951).
    [Show full text]
  • Cobalt Toxicity in Humans. a Review of the Potential Sources and Systemic Health Effects
    Cobalt toxicity in humans. A review of the potential sources and systemic health effects. Laura Leyssensa, Bart Vincka,b, Catherine Van Der Straetenc,d, Floris Wuytse,f, Leen Maesa,g. a Faculty of Medicine and Health Sciences, University of Ghent (Belgium) Department of Speech, Language and Hearing Sciences University Hospital Ghent, policlinic 1 floor 2 De Pintelaan 185 9000 Ghent Belgium [email protected] (corresponding author) [email protected] b Faculty of Humanities, University of Pretoria (South Africa) Department of Speech-Language Pathology and Audiology Aula Theatre, University Road Pretoria, 0001 South Africa [email protected] c Faculty of Medicine, Imperial College London Department of Surgery & Cancer Musculoskeletal Sciences and Technology Imperial College London Charing Cross Campus, 7L21 Lab Block London SW7 2AZ UK [email protected] d Faculty of Medicine and Health Sciences, University of Ghent (Belgium) De Pintelaan 185 9000 Ghent Belgium e Antwerp University Research center for Equilibrium and Aerospace (AUREA) Department of Otorhinolaryngology University Hospital Antwerp Campus Groenenborger Groenenborgerlaan 171 2020 Antwerp Belgium [email protected] f Department of Biomedical Physics, University of Antwerp (Belgium) Campus Groenenborger Groenenborgerlaan 171 2020 Antwerp Belgium g Clinical audiology department University Hospital Ghent De Pintelaan 185 9000 Ghent Belgium 1 Abstract Cobalt (Co) and its compounds are widely distributed in nature and are part of numerous anthropogenic activities. Although cobalt has a biologically necessary role as metal constituent of vitamin B12, excessive exposure has been shown to induce various adverse health effects. This review provides an extended overview of the possible Co sources and related intake routes, the detection and quantification methods for Co intake and the interpretation thereof, and the reported health effects.
    [Show full text]
  • Densifying Metal Hydrides with High Temperature and Pressure
    3,784,682 United States Patent Office Patented Jan. 8, 1974 feet the true density. That is, by this method only theo- 3,784,682 retical or near theoretical densities can be obtained by DENSIFYING METAL HYDRIDES WITH HIGH making the material quite free from porosity (p. 354). TEMPERATURE AND PRESSURE The true density remains the same. Leonard M. NiebylsM, Birmingham, Mich., assignor to Ethyl Corporation, Richmond, Va. SUMMARY OF THE INVENTION No Drawing. Continuation-in-part of abandoned applica- tion Ser. No. 392,370, Aug. 24, 1964. This application The process of this invention provides a practical Apr. 9,1968, Ser. No. 721,135 method of increasing the true density of hydrides of Int. CI. COlb 6/00, 6/06 metals of Groups II-A, II-B, III-A and III-B of the U.S. CI. 423—645 8 Claims Periodic Table. More specifically, true densities of said 10 metal hydrides may be substantially increased by subject- ing a hydride to superatmospheric pressures at or above ABSTRACT OF THE DISCLOSURE fusion temperatures. When beryllium hydride is subjected A method of increasing the density of a hydride of a to this process, a material having a density of at least metal of Groups II-A, II-B, III-A and III-B of the 0.69 g./cc. is obtained. It may or may not be crystalline. Periodic Table which comprises subjecting a hydride to 15 a pressure of from about 50,000 p.s.i. to about 900,000 DESCRIPTION OF THE PREFERRED p.s.i. at or above the fusion temperature of the hydride; EMBODIMENT i.e., between about 65° C.
    [Show full text]
  • Alternative Testing Approaches in Environmental Safety Assessment
    Alternative Testing Approaches in Environmental Safety Assessment Technical Report No. 97 ISSN-0773-8072-97 Brussels, December 2005 Alternative Testing Approaches in Environmental Safety Assessment ECETOC TECHNICAL REPORT No. 97 © Copyright - ECETOC AISBL European Centre for Ecotoxicology and Toxicology of Chemicals 4 Avenue E. Van Nieuwenhuyse (Bte 6), B-1160 Brussels, Belgium. All rights reserved. No part of this publication may be reproduced, copied, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the copyright holder. Applications to reproduce, store, copy or translate should be made to the Secretary General. ECETOC welcomes such applications. Reference to the document, its title and summary may be copied or abstracted in data retrieval systems without subsequent reference. The content of this document has been prepared and reviewed by experts on behalf of ECETOC with all possible care and from the available scientific information. It is provided for information only. ECETOC cannot accept any responsibility or liability and does not provide a warranty for any use or interpretation of the material contained in the publication. ECETOC TR No. 97 Alternative Testing Approaches in Environmental Safety Assessment Alternative Testing Approaches in Environmental Safety Assessment CONTENTS SUMMARY 1 1. INTRODUCTION 3 2. BACKGROUND 5 2.1 Definitions 5 2.1.1 Definition of a protected animal 5 2.1.2 Ethical considerations of animal use 6 2.1.3 The three Rs 6 2.2 Information needs 7 2.2.1 The use of fish in ecotoxicology 7 2.2.2 Numbers of fish used 8 2.2.3 Regulatory tests - chemicals 8 2.2.4 REACH and its impact on the use of fish 9 2.2.5 Regulatory tests - effluents 9 2.3 Potential for alternatives 10 2.3.1 Reduction 10 2.3.2 Refinement 11 2.3.3 Replacement 11 2.4 Report structure 13 2.4.1 Atmosphere 14 2.4.2 Terrestrial hazard assessment 14 3.
    [Show full text]
  • Iron Dysregulation in Movement Disorders
    Neurobiology of Disease 46 (2012) 1–18 Contents lists available at SciVerse ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Review Iron dysregulation in movement disorders Petr Dusek a,c, Joseph Jankovic a,⁎, Weidong Le b a Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA b Parkinson's Disease Research Laboratory, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA c Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic article info abstract Article history: Iron is an essential element necessary for energy production, DNA and neurotransmitter synthesis, myelination Received 9 November 2011 and phospholipid metabolism. Neurodegeneration with brain iron accumulation (NBIA) involves several genetic Revised 22 December 2011 disorders, two of which, aceruloplasminemia and neuroferritinopathy, are caused by mutations in genes directly Accepted 31 December 2011 involved in iron metabolic pathway, and others, such as pantothenate-kinase 2, phospholipase-A2 and fatty acid Available online 12 January 2012 2-hydroxylase associated neurodegeneration, are caused by mutations in genes coding for proteins involved in phospholipid metabolism. Phospholipids are major constituents of myelin and iron accumulation has been linked Keywords: Iron to myelin derangements. Another group of NBIAs is caused by mutations in lysosomal enzymes or transporters Neurodegeneration such as ATP13A2, mucolipin-1 and possibly also β-galactosidase and α-fucosidase. Increased cellular iron uptake Dystonia in these diseases may be caused by impaired recycling of iron which normally involves lysosomes.
    [Show full text]
  • Modifying Antirheumatic Drugs in Active Rheumatoid Arthritis: a Japan Phase 3 Trial (HARUKA)
    MODERN RHEUMATOLOGY 2020, VOL. 30, NO. 2, 239–248 https://doi.org/10.1080/14397595.2019.1639939 ORIGINAL ARTICLE Sarilumab monotherapy or in combination with non-methotrexate disease- modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA) Hideto Kamedaa, Kazuteru Wadab, Yoshinori Takahashib, Owen Haginoc, Hubert van Hoogstratend, Neil Grahame and Yoshiya Tanakaf aDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University (Ohashi Medical Center), Tokyo, Japan; bSanofi K.K., Tokyo, Japan; cSanofi, Bridgewater, NJ, USA; dSanofi-Genzyme, Cambridge, MA, USA; eRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; fFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Downloaded from https://academic.oup.com/mr/article/30/2/239/6299750 by guest on 01 October 2021 Japan, Kitakyushu, Japan ABSTRACT ARTICLE HISTORY Objectives: To determine long-term safety and efficacy of sarilumab as monotherapy or with non- Received 13 March 2019 methotrexate (MTX) conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in Accepted 1 July 2019 Japanese patients with active rheumatoid arthritis (RA). KEYWORDS Methods: In this double-blind, randomized study (NCT02373202), patients received subcutaneous sari- Rheumatoid arthritis; lumab 150 mg q2w (S150) or 200 mg q2w (S200) as monotherapy or with non-MTX csDMARDs for 52 sarilumab; Japan; phase III; weeks. The primary endpoint was safety. anti-IL-6 receptor Results: Sixty-one patients received monotherapy (S150, n ¼ 30; S200, n ¼ 31) and 30 received combin- ation therapy (S150 þ csDMARDs, n ¼ 15; S200 þ csDMARDs, n ¼ 15). Rates of treatment-emergent adverse events (TEAEs) were 83.3%/90.3%/93.3%/86.7% for S150/S200/S150 þ csDMARDs/ S200 þ csDMARDs, respectively.
    [Show full text]
  • Study Protocol);
    PF-06651600 B7981006 Final Protocol Amendment 1, 26 October 2016 A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06651600 IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE Investigational Product Number: PF-06651600 Investigational Product Name: Not Applicable (N/A) United States (US) Investigational New 131274 Drug (IND) Number: European Clinical Trials Database 2016-002862-30 (EudraCT) Number: Protocol Number: B7981006 Phase: 2a Page 1 PF-06651600 B7981006 Final Protocol Amendment 1, 26 October 2016 Document History Document Version Date Summary of Changes and Rationale Amendment 1 26 October 2016 In the Schedule of Activities, and Section 7.2.12, added audiogram testing Rationale: To monitor for potential changes in hearing between baseline [between Visit 1 and Visit 2 (inclusive)] and at the end of the study [between Visit 7 and Visit 9 (inclusive)]. The following exclusion criteria has been added in Section 4.2: Have current or recent history of clinically significant severe or progressive hearing loss or auditory disease. Subjects with hearing aids will be allowed to enter the study provided their hearing impairment is considered controlled/ clinically stable. Rationale: This has been added to ensure that subject hearing for safety is fully evaluated prior to study entry. Several additional minor changes were made to protocol language for the purposes of clarification. Original protocol 31 August 2016 Not applicable (N/A) This amendment incorporates all revisions to date, including amendments made at the request of country health authorities and institutional review boards (IRBs)/ethics committees (ECs).
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • New Brunswick Drug Plans Formulary
    New Brunswick Drug Plans Formulary August 2019 Administered by Medavie Blue Cross on Behalf of the Government of New Brunswick TABLE OF CONTENTS Page Introduction.............................................................................................................................................I New Brunswick Drug Plans....................................................................................................................II Exclusions............................................................................................................................................IV Legend..................................................................................................................................................V Anatomical Therapeutic Chemical (ATC) Classification of Drugs A Alimentary Tract and Metabolism 1 B Blood and Blood Forming Organs 23 C Cardiovascular System 31 D Dermatologicals 81 G Genito Urinary System and Sex Hormones 89 H Systemic Hormonal Preparations excluding Sex Hormones 100 J Antiinfectives for Systemic Use 107 L Antineoplastic and Immunomodulating Agents 129 M Musculo-Skeletal System 147 N Nervous System 156 P Antiparasitic Products, Insecticides and Repellants 223 R Respiratory System 225 S Sensory Organs 234 V Various 240 Appendices I-A Abbreviations of Dosage forms.....................................................................A - 1 I-B Abbreviations of Routes................................................................................A - 4 I-C Abbreviations of Units...................................................................................A
    [Show full text]
  • New Generation Cadmium‑Free Quantum Dots for Biophotonics and Nanomedicine
    This document is downloaded from DR‑NTU (https://dr.ntu.edu.sg) Nanyang Technological University, Singapore. New Generation Cadmium‑Free Quantum Dots for Biophotonics and Nanomedicine Xu, Gaixia; Zeng, Shuwen; Zhang, Butian; Swihart, Mark T.; Yong, Ken‑Tye; Prasad, Paras N. 2016 Xu, G., Zeng, S., Zhang, B., Swihart, M. T., Yong, K.‑T., & Prasad, P. N. (2016). New Generation Cadmium‑Free Quantum Dots for Biophotonics and Nanomedicine. Chemical Reviews, 116(19), 12234‑12327. https://hdl.handle.net/10356/83973 https://doi.org/10.1021/acs.chemrev.6b00290 © 2016 American Chemical Society. This is the author created version of a work that has been peer reviewed and accepted for publication by Chemical Reviews, American Chemical Society. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1021/acs.chemrev.6b00290]. Downloaded on 06 Oct 2021 00:28:06 SGT Page 1 of 288 Submitted to Chemical Reviews 1 2 3 4 5 6 New Generation Cadmium-Free Quantum Dots for 7 8 Biophotonics and Nanomedicine 9 10 11 12 13 14 Gaixia Xu1,5†, Shuwen Zeng2,5†, Butian Zhang2, Mark T. Swihart3*, 15 2* 4* 16 Ken-Tye Yong and Paras N. Prasad 17 18 19 20 1 21 Key Laboratory of Optoelectronics Devices and Systems of Ministry of Education/Guangdong 22 Province, College of Optoelectronic Engineering, Shenzhen University, Shenzhen, P. R. 23 China 24 2 25 School of Electrical and Electronic Engineering,
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]